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Abstract Attention-deficit/hyperactivity disorder (ADHD)
is one of the most common neurodevelopmental disorders
among school-aged children. It is highly symptomatic and
associated with significant impairment. This review exam-
ines the role of stimulant medications in the treatment of
children and adolescents with ADHD. Published clinical
studies that compared methylphenidate- and amfetamine-
based stimulants in children and adolescents with ADHD
support the therapeutic utility of stimulant treatments, and
suggest robust efficacy and acceptable safety outcomes in
groups treated with either stimulant. Evidence-based guide-
lines agree that each patient with ADHD is unique and indi-
vidual treatment strategies that incorporate both drug and
non-drug treatment options should be sought. In seeking to
optimize individual response and outcomes to stimulant
therapy, important considerations include the selection of
stimulant class, the choice of long- or short-acting stimulant
formulations, addressing effectively any emergent adverse
effects and strategies aimed at enhancing adherence to dosing
regimen and persistence on therapy.
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CGI-I Clinical global impressions-improvements
CI Confidence interval
CPRS-R Conners’ Parent Rating Scale-Revised
CTRS Conners’ Teacher Rating Scale
CTRS-R Conners’ Teacher Rating Scale-Revised
d-AMF Dexamfetamine
5-HT 5-Hydroxytryptamine
IOWA Inattention/overactivity with aggression
LDX Lisdexamfetamine dimesylate
MAS Mixed amfetamine salts
MPH Methylphenidate
MTA Multimodal treatment study of children
with ADHD
OROS MPH Osmotic release oral system methylphenidate
SD Standard deviation
SH Spontaneously hypertensive
SMD Standardized mean difference
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one of the
most common neurodevelopmental disorders among school-
aged children, with a worldwide prevalence estimated to be
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5.29 % (95 % confidence interval [CI], 5.01–5.56 %),
based on a meta-analysis of 102 studies incorporating more
than 170,000 participants from all continents [79]. ADHD
is a heterogenous disorder that is, however, characterized
by the core symptoms of inattention and hyperactivity/
impulsivity [2]. ADHD results in significant impairment,
and its treatment should address both the core symptoms
and any comorbid conditions, behavioural or psychosocial
impairments, and learning difficulties that may be present
[17, 66, 75, 91].
This review examines the role of stimulant medications
as part of a multimodal treatment strategy in children and
adolescents with ADHD. The review first explores the
place of stimulant medications in clinical treatment
guidelines around the world and then briefly reviews the
overlapping but distinct mechanisms of actions of the
methylphenidate (MPH) and amfetamine (AMF) classes of
stimulant in the pathophysiology of ADHD. Next, we
provide an update of direct and indirect clinical compari-
sons of efficacy of these stimulants in the treatment of
ADHD. Finally, we discuss the role of stimulants within a
comprehensive strategy aimed at optimizing treatment for
the benefit of an individual with ADHD and their family
members or caregivers.
Treatment recommendations in clinical guidelines
Guidelines from around the world differ in their treatment
recommendations [85]. There is, however, general agree-
ment that a comprehensive, multimodal treatment plan
should be developed by the clinician, patient and family
working closely together. In this plan, psychoeducation,
parent/caregiver management training, behavioural and
educational intervention, and medications are balanced to
create the optimum treatment paradigm for each individual
with ADHD [1, 15, 17, 66, 75, 77, 91, 93]. Specific treat-
ment plans will be based, in part, on problems and
impairments identified for the child and on access to and
funding of healthcare resources. These differ by jurisdic-
tion and geography, both between and within different
countries.
Considerable evidence has accumulated over several
decades that most patients with ADHD symptoms can be
successfully treated by psychopharmacotherapies [33, 61]
as part of a comprehensive treatment approach. Short- and
long-acting formulations of the stimulants MPH and AMF,
including the recently introduced AMF prodrug lis-
dexamfetamine dimesylate (LDX), the selective noradren-
aline reuptake inhibitor atomoxetine, and the a2 adrenergic
receptor agonists clonidine and guanfacine (including
short- and long-acting formulations) are all approved by
the US Food and Drug Administration (FDA). However,
the range of ADHD medications available to patients and
physicians is not as extensive in many countries outside
North America. In the USA, the American Academy of
Child and Adolescent Psychiatry Practice Parameters rec-
ommend that treatment plans consist of psychopharmaco-
therapy and/or behavioural therapy. The initial medication
should be one of the following FDA-approved drugs: MPH,
AMF, mixed amfetamine salts, or atomoxetine [1, 75, 77].
The American Academy of Pediatrics (AAP) recommends
that pre-school children receive behavioural therapy, with
MPH only prescribed if moderate-to-severe dysfunction
remains. For school-aged children, the AAP recommends
FDA-approved medications and/or behavioural therapy,
and for adolescents recommends the use of medications
and that behavioural therapy may be used. With regard to
medications, the AAP considers the evidence of efficacy to
be particularly strong for stimulants and less strong for
atomoxetine, long-acting guanfacine and long-acting clo-
nidine [1, 75, 77]. The noradrenaline and dopamine reup-
take inhibitor bupropion and tricyclic antidepressants,
including imipramine, are listed within US guidelines as
medication options for ADHD, but are not approved [75].
In Australia, MPH and AMF are also both recommended as
first-line treatments [93], and in Canada, long-acting
preparations of MPH and AMF or atomoxetine are all
considered to be the first-line treatments [17].
In European countries, pre-school children and school-
age children with ADHD with moderate impairment, psy-
choeducation and behavioural intervention are generally
recommended as first-line treatment. In cases of severe
ADHD with severe impairment, of moderate impairment
that has failed to respond to psychoeducation, and when
behavioural interventions are unavailable, medication
should be offered [66, 91]. MPH, in short- or long-acting
formulations, is generally recommended as the first choice
medication for ADHD in Europe. Atomoxetine, though
generally less effective than stimulants, is also widely
available and may be recommended as an alternative to
MPH [9, 24, 57, 63, 66, 84, 91]. AMF formulations are less
widely available, typically due to either not being approved
by regulatory agencies or not being placed on national
formularies. Unusually within Europe, both MPH and
AMF classes of stimulant are approved in the UK and are
covered in national guidelines. In England and Wales,
treatment algorithms recommend MPH as the first-line
medication for ADHD, with atomoxetine as a second-line
option. Although short-acting AMF is approved for
ADHD, the National Institute of Health and Clinical
Excellence (NICE) considered that the published trials
were not of good enough quality to be included in their
review, and so AMF is recommended only when symp-
toms are unresponsive to the maximum tolerated dose of
MPH or atomoxetine [66]. National recommendations are
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reflected by a marked imbalance in prescribing patterns for
the two classes of stimulant for the treatment of ADHD, the
numbers of prescriptions in England (2010 figures) for
MPH and AMF were 661,463 and 45,519, respectively
[65]. Even in Scotland, where short-acting AMF is con-
sidered as a potential second-line treatment, it is prescribed
disproportionately less frequently than MPH. In addition to
the stimulants and atomoxetine, clonidine, guanfacine,
bupropion, modafinil and tricyclic antidepressants are lis-
ted within European guidelines, but are not approved, as
medication options for ADHD [66, 91].
Long-acting stimulant formulations are as efficacious as
their short-acting counterparts. In a meta-analysis of 32
clinical studies in children and adolescents (mean ages
within studies ranged from 8 to 15 years), there was no
difference in effect sizes for dependent measures (stan-
dardized mean difference [SMD]; 95 % CI) observed for all
studies that investigated short-acting (0.99; 0.88–1.1) and
long-acting stimulants (0.95; 0.85–1.1) [38]. Long-acting
stimulants offer the advantages of not having to be taken
during the school day, thereby reducing stigma for the
patient and the logistical problems for the school of storing
and administering scheduled medications. In addition,
once-daily formulations result in enhanced compliance,
more consistent and extended coverage throughout the day,
and reduced abuse potential than short-acting formulations
[9, 75]. Short-acting stimulants have the advantages of
greater flexibility of dosing and lower cost. Guidelines
recommend that individual clinical choice will determine
whether long- or short-acting stimulant medications should
be used [9]. However, some guidelines (Canada) recom-
mend the use of long acting stimulants as first line [17].
In vitro and in vivo pharmacologies of MPH and AMF
The aetiology of ADHD is complex, with multiple genetic
and non-genetic factors implicated [22, 41]. However,
recent evidence has converged to suggest that catechol-
amine neurotransmission is impaired in the brains of
patients with ADHD [6, 7, 13]. Furthermore, stimulants
and the non-stimulant atomoxetine increase synaptic cate-
cholamine concentrations in the brain, particularly in the
prefrontal cortex, although their precise mechanisms of
action differ (Fig. 1).
The primary molecular targets of MPH are plasma mem-
brane dopamine and noradrenaline transporters [60]. In vitro
experiments demonstrate that uptake of dopamine and nor-
adrenaline is inhibited by dl-threo-MPH with modest potency
(inhibition constant [Ki], 160–341 and 40–238 nM, respec-
tively) [49]. Intraperitoneal administration of dl-threo-MPH
10 mg/kg to spontaneously hypertensive rats elicits a
rapid 3–4-fold increase in extracellular concentrations of
noradrenaline in the prefrontal cortex and dopamine in the
striatum, peaking within 45 min of dosing, and remaining
above control levels for at least 3 h [48].
Like MPH, d-AMF inhibits uptake of dopamine and
noradrenaline with modest potency (Ki 34–225 and
39–55 nM, respectively). Unlike MPH, d-AMF also
inhibits 5-hydroxytryptamine (5-HT) uptake (Ki 1.4–3.8 lM)
[49]. d-AMF also induces the release of monoamines from
presynaptic terminals [49], possibly via mechanisms that
include an interaction with vesicular monoamine trans-
porter 2, and the reversal of plasma membrane monoamine
transporters [30, 52, 53, 82, 90]. Evidence of a weak
affinity for monoamine oxidase (Ki 20 lM) suggests that
d-AMF also inhibits the metabolism of monoamines [49].
Intraperitoneal administration of d-AMF 1 mg/kg to
spontaneously hypertensive rats elicits a 15-fold increase in
striatal dopamine concentrations 30 min post-dose that
return to control levels within 90 min, and a fourfold
increase in noradrenaline concentrations in the prefrontal
Fig. 1 Overlapping but distinct putative mechanisms of action of
a methylphenidate (MPH) and b amfetamine (AMF) at the dopamine
synapse. VMAT2 vesicular monoamine transporter 2
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cortex within 45 min of dosing that remain above control
levels for at least 3 h. Unlike MPH, d-AMF also elicits
elevations in extracellular 5-HT concentrations in vivo
[55].
Clinical comparisons of MPH and AMF
Table 1 presents a summary of the MPH- and AMF-based
stimulants that are used in the treatment of ADHD. In
clinical studies, the efficacy and side effects of a treatment
in respect of a particular outcome measure may be assessed
at the overall group mean or individual level (response
rate). There are multiple methods for comparing the effi-
cacy of ADHD medications. The strongest evidence is
provided by direct, head-to-head, parallel-group studies.
However, the paucity of such studies means that other
clinical trial designs, including crossover studies and meta-
analyses, must be used to compare efficacy across stimu-
lant treatments.
Search strategy for the identification of published
clinical comparisons of MPH and AMF
PubMed literature searches were conducted (in March
2011) for papers containing combinations of MPH-based
Table 1 Structure of amfetamine (AMF) and methylphenidate (MPH), and examples of commercial formulations used in the treatment of
ADHD




Drug Composition Duration of
action (h)
Amfetamine (AMF, International Non-Proprietary Name)
Adderall (mixed salts
of dl-AMF)
4–6 [3] Adderall XR
















4–6 [3] VyvanseTM (d-AMF) Prodrug 13–14 [17]
Methylphenidate (MPH)
Focalin (d-MPH) 4 [3] Biphentin (racemic MPH) Capsulated biphasic
beads
10–12 [17]















8 [3, 9, 62]
Methylin
(racemic MPH)





4 [3, 62] Metadate ER
(racemic MPH)








Wax matrix tablets 8 [3, 62]
Methylphenidate SR
(racemic MPH)
Wax matrix tablets 8 [3]
Ritalin LA (racemic MPH) Capsulated biphasic
beads
8–10 [62]
Ritalin SR (racemic MPH) Wax matrix tablets 8 [3, 62]
ADHD attention-deficit/hyperactivity disorder, d-AMF dexamfetamine, dl-AMF racemic amfetamine, MPH methylphenidate
a Subdivided into intermediate and long-acting formulations by some authors [27, 75]
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studies (search terms: methylphenidate, Biphentin, Con-
certa, Daytrana, Equasym, Focalin, Medikinet, Metadate,
Methylin, Ritalin) and AMF-based studies (search terms:
amfetamine, Adderall, Dexedrine, Dextrostat, lisdexamfe-
tamine). Results were limited to ‘clinical trial’ but were not
limited by publication date. A total of 176 references were
identified, of which 150 had English language abstracts.
Identified papers were filtered for relevance based on the
content of their abstracts. Inclusion criteria for references
were the reporting of clinical outcome data (not bio-
chemical, cytotoxicological, or preclinical data), concerned
with ADHD and its treatment (not drug abuse, drug abuse
liability, or comorbid symptoms such as tics), reported
randomized, double-blind, controlled trials (not open label
or n-of-1 trials), and reported comparisons of MPH- and
AMF-based stimulants (not pooled stimulant groups or
studies in which one or other stimulant was a simple
positive control).
Direct clinical comparisons of MPH and AMF
Head-to-head comparisons
The results of the search for published randomized clinical
studies that directly compare MPH- and AMF-based
stimulants are shown in Table 2. Of the 13 published
studies that were identified, there was one parallel-group
(i.e. head-to-head) study [76]. This study compared short-
acting mixed AMF salts (MAS) with short-acting MPH in
the treatment of 58 children with ADHD. As the result of a
dose optimization protocol designed to arrive at the ideal
balance between efficacy and side-effects, mean daily
doses of short-acting MAS and MPH in the final week of
the study were 12.5 and 25.2 mg, respectively. The mean
daily inattention/overactivity factor of the Inattention/
Overactivity with Aggression (IOWA) Conners’ Teacher
Rating Scale (CTRS) in the MAS-treated group (mean
0.49) was statistically superior to that of the MPH-treated
group (mean 0.81), and both were statistically superior to
placebo (mean 1.49). Similarly, the aggression/defiance
factor of the IOWA CTRS in the MAS group (mean 0.29)
was statistically superior to the MPH group (mean 0.49),
and both were statistically superior to placebo (mean 0.72).
Further, patients treated with MAS were superior to MPH
in the Clinical Global Impressions-Improvements (CGI-I)
scale (means 1.6 and 2.35 for the MAS- and MPH-treated
patients, respectively) and both were superior to placebo
(mean 3.22). The proportion of responders (i.e. improve-
ment in CGI-I scores of 1 or 2) also favoured MAS treat-
ment (MAS 90 %, MPH 65 %, and placebo 27 %) [76]. As
will be discussed later, there was no statistical difference in
parent-reported side-effects of moderate or severe intensity
at the end of the study. Thus, evidence from this parallel-
group comparison suggests the superiority of short-acting
AMF- over short-acting MPH-based stimulants at opti-
mized daily doses. The authors acknowledged, however,
that the dose-optimization algorithm employed, may have
limited dosing in the methylphenidate group [76]. It is also
possible that the group differences could be a consequence
of the longer half-life, and subsequent longer duration of
action, of the MAS preparation (up to 6 h) compared to the
MPH preparation (up to 4 h).
Crossover studies
An advantage of crossover clinical trials is that the within-
group design permits the comparison of the treatments in
each individual patient, rather than at the group or popu-
lation level only. A previous comparative review [4] of
crossover studies of short-acting formulations of AMF and
MPH found no consistent statistical differences in group
means of outcome measures. Of a total of 174 patients in six
crossover studies, 48 (28 %) responded better to AMF and
27 (16 %) responded better to MPH, and at least 72 (41 %)
responded to both; in all studies except for one in which
patients exhibited comorbid Tourette’s syndrome, there was
a non-significant trend for superior response in patients
treated with AMF over those treated with MPH [4].
Most of the crossover studies listed in Table 2 that
compared the efficacy of MPH and AMF in patients with
ADHD reported equivalence in outcome measures for the
two classes of stimulant at the level of the group mean.
Those studies that observed statistical superiority of one
stimulant over the other for particular outcome measures
are reviewed below.
Studies that reported outcomes that favoured MPH
included an Australian study, in which 125 treatment-naı¨ve
children (aged 5–15 years) were randomly assigned to
receive either MPH or AMF [31]. Doses were fixed and
based on body weight (short-acting MPH 0.3 mg/kg twice
daily; short-acting AMF 0.15 mg/kg twice daily). After
2 weeks of treatment, both stimulants induced significant
improvements in baseline scores for all factors of the
Conners’ Teacher Rating Scale-Revised (CTRS-R) and
the Conners’ Parent Rating Scale-Revised (CPRS-R). In
the CTRS-R, there was a statistically significant difference
(MPH effect minus AMF effect) in favour of MPH in
treatment-induced improvements in conduct problems
(difference 3.31, 95 % CI 1.11–5.50, p \ 0.01), hyper-
activity factor (difference 2.78, 95 % CI 0.70–4.86,
p \ 0.01), inattentive-passive factor (difference 1.61, 95 %
CI 0.30–2.92, p = 0.02) and hyperactivity index (differ-
ence 2.60, 95 % CI 0.69–4.51, p \ 0.01). In the CPRS-R,
the difference in improvement in favour of MPH reached
statistical significance for the anxiety factor only
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(difference 1.20, 95 % CI 0.19–2.20, p = 0.02) [31]. In
another study in which short-acting stimulant formulations
of MPH 0.45–1.25 mg/kg and AMF 0.2–0.6 mg/kg were
administered at breakfast and lunchtime to 18 boys (mean
age 9.6 years), both stimulants significantly reduced motor
activity (truncal activity counts per hour) compared with
placebo, but the reduction was greater for MPH than
for AMF between the hours of 11 a.m. and 1 p.m. [12].
A recent crossover study compared the effects of the long-
acting stimulant formulations osmotic release oral system
MPH (OROS MPH; maximum daily dose 72 mg) and
extended-release MAS (maximum daily dose 30 mg) on
neuropsychological functioning in adolescents with ADHD
(n = 35; mean age 17.5 years) [98]. There were no sig-
nificant differences between OROS MPH and extended-
release MAS in any of the outcomes studied. However,
OROS MPH, but not extended-release MAS, was statisti-
cally superior to placebo in distracter errors and distracter
reaction time in the Go/No-Go test and in Recall Accuracy
in the Delayed Matching-to-Sample test, perhaps reflecting
greater than a twofold MPH to AMF dose-ratio than that
considered to be equivalent [98, 101].
In contrast to the above results favouring MPH,
responses to short-acting AMF (maximum daily dose
45 mg) were superior to short-acting MPH (maximum
daily dose 90 mg) in a crossover study of classroom per-
formance in boys aged 6–12 years with ADHD. Compared
with placebo, both drugs produced statistically significant
improvements in performance (percent correct responses)
and number of problems attempted for reading tasks, and
both drugs improved the number of attempted arithmetic
problems. However, improved performance in arithmetic
problems compared with placebo was statistically signifi-
cant for AMF only (mean [standard deviation] percent
correct: AMF 97.1 [4.6]; MPH 96.2 [5.6]; placebo 94.0
[7.9]) [36]. Again, the longer duration action of the
amphetamine may have influenced these results.
Meta-analyses
Using standardized effect sizes, it is possible indirectly to
compare efficacy outcomes for particular treatments across
studies. Standardized mean difference (SMD) is one way of
calculating effect size. For example, an SMD of 1 indicates
that the mean outcomes in drug and placebo groups differ
by 1 (pooled) standard deviation. In interpreting SMD
values, an SMD of 0.2 is considered small, 0.5 is consid-
ered medium, and C0.8 is considered large [21] (Fig. 2).
A series of recent meta-analyses have examined effect
sizes of various outcome measures in patients with ADHD
of different ages treated with different ADHD medications
[38–40]. In a meta-analysis of 32 double-blind, placebo-
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meta-analysis regression found that effect sizes for non-
stimulant medications (SMD = 0.57) were significantly
smaller than for both short-acting (SMD = 0.99,
F1,31 = 25, p \ 0.0001) and long-acting stimulants
(SMD = 0.95, F1,31 = 15, p \ 0.0001) [38]. Although this
analysis did not stratify stimulant therapies according to
their MPH or AMF class, it is interesting to note that the
largest effect sizes for both short-acting (MAS,
SMD = 1.34) and long-acting (LDX, SMD = 1.52) stim-
ulants were seen for AMF-based therapies. When effect
sizes were compared across 23 randomized, controlled
trials of 11 different short- and long-acting stimulants in
children and adolescents with ADHD, robust drug effects
were observed in all individual studies. Furthermore, across
all of these studies, effect sizes for AMF products were
significantly greater than for MPH products (SMD = 1.03
vs. 0.77, t19 = 2.5, p = 0.02). Regression analyses
found that several study variables, including stimulant
formulation (short-acting vs. long-acting), type of dosing
(fixed vs. optimized), and study design (parallel vs. cross-
over), were not associated with SMD. It is, of course,
possible that heterogeneity between study variables may
have obscured possible associations between these vari-
ables and SMD. Nevertheless, three study design features
were identified that they were associated with SMD (age,
type of score [outcome or change], and rater [physician,
parent, teacher, or patient]), but the finding that effect sizes
for AMF were modestly greater than those for MPH held
after correcting for these confounding variables [39].
Equivalence of dosing between AMF and MPH stimulants
was not demonstrated. Using the method of numbers nee-
ded to treat, another way of comparing outcomes from
different studies, the authors calculated that 2.0 patients
were needed to be treated with AMF for each positive
outcome for total ADHD symptoms compared with 2.6
patients for MPH [39]. Overall, these pooled analyses
provide strong evidence for the efficacy of stimulant
medications in ADHD, while one meta-analysis provides
evidence of the greater efficacy of AMF-based drugs
compared with MPH-based drugs in children and adoles-
cents. Again, the longer duration action of short-acting
AMF than short-acting MPH may have contributed to these
results.
Summary of clinical comparisons
Overall, some individual studies have demonstrated supe-
riority of MPH over AMF, some have found superiority of
Fig. 2 Effect sizes and
confidence intervals for ADHD-
RS and CGI outcomes in
children. Black diamonds and
horizontal black lines represent
standardized mean difference
effect sizes and 95 %
confidence intervals,
respectively. Pooled results are
depicted as open diamonds with
the effect size in the centre of
the diamond and the 95 %
confidence intervals depicted by
the left and right extremities of
the diamond. ADHD-RS
attention-deficit/hyperactivity
disorder rating scale, CGI
clinical global impressions of
ADHD severity, LDX
lisdexamfetamine dimesylate,
MAS mixed amfetamine salts,
MPH methylphenidate, OROS
osmotic release oral system, TS
transdermal system. Figure
adapted from Faraone [37], with
permission
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AMF over MPH, and others have shown no differences
between the two types of medications. When meta-analyses
are performed summarizing all available evidence, the
effect sizes observed with AMF are greater than those
observed with MPH, although issues of comparable dosing
and differences in the duration of action of short-acting
stimulants should be taken into account when interpreting
these data. However, given the currently available evi-
dence, it has not been demonstrated that one stimulant is
more efficacious than another at a population level; direct
head-to-head studies would be required to establish this
definitively.
Tolerability of stimulant medications
There is considerable overlap in the adverse event profiles
of MPH- and AMF-based ADHD medications [46, 47]. In
the parallel-group comparison of MPH and MAS in chil-
dren with ADHD, the adverse events reported in more than
10 % of patients in the MPH treatment group were tired-
ness, appetite loss, irritability, and anxiousness; in the
MAS group they were stomach ache, irritability, negative
emotion (sadness, tearfulness), appetite loss, tiredness, and
headache [76]. The incidences of stomach ache and nega-
tive emotion were numerically greater in the MAS group
than in the MPH group but the differences were not sig-
nificant after applying the Bonferroni correction for mul-
tiple statistical tests [76].
In crossover studies, insomnia and appetite suppression
were generally reported to be the most common adverse
events for both classes of stimulant [46, 47]. The severities
(but not frequencies) of insomnia, irritability, proneness to
crying, anxiousness, sadness, unhappiness, and nightmares
were all reported to be greater in children treated with
AMF 0.15 mg/kg twice daily than with MPH 0.3 mg/kg
twice daily [32]. The incidence of overall adverse events
has been reported to be numerically greater in children
receiving long-acting AMF 10 mg/day than in those
receiving short-acting MPH 10 mg twice daily or long-
acting MPH 20 mg/day [72]. Furthermore, in a comparison
of the safety and tolerability of short-acting MPH 10 and
17.5 mg twice daily and MAS 7.5 and 12.5 mg twice daily,
parent-rated incidences of moderate-to-severe (on average)
trouble sleeping and loss of appetite were greater in high-
dose, MAS-treated patients (trouble sleeping 12 %, loss of
appetite 24 %) than in high-dose, MPH-treated patients
(trouble sleeping 4 %, loss of appetite 4 %) [68]. Finally,
over 3 weeks’ dosing, mean weight loss was significantly
greater than placebo in girls treated with AMF (maximum
dose 0.64 mg/kg twice daily, mean [standard deviation]
change from baseline -1.1 kg [1.0 kg], p \ 0.01) but not
MPH (maximum dose 1.28 mg/kg twice daily, mean
[standard deviation] change from baseline -0.4 kg [1.1 kg],
not significant) [86].
In contrast, nervous habits and mannerisms have been
reported as being more common in boys treated with MPH
(maximum mean dose 2.5 mg/kg twice daily), but not
AMF (maximum mean dose 1.3 mg/kg twice daily), than
in those treated with placebo [35]. In addition, the inci-
dence of stomach aches in children was lower with AMF
(mean dose 18.5 mg/day), but not MPH (mean dose
37.9 mg/day), than with placebo [5].
Based on the reviewed studies, the adverse event
profiles of the two classes of stimulants appear to be
similar. Some studies suggest that the frequency and
severity of adverse events may be somewhat greater with
AMF than with MPH products when AMF is compared
with MPH, whereas side effects with MPH may be more
common than with AMF when both drugs are compared
with placebo.
Optimizing medication for an individual
The aim of optimizing an individual’s medication strategy
is to achieve the maximum reduction of symptoms, or even
the remission of ADHD, without the appearance of intol-
erable side effects. While it used to be the case that
improvement in symptoms was the primary goal of treat-
ment, clinicians are increasingly seeking treatment strate-
gies that result in remission of ADHD in an individual. By
remission we mean the loss of diagnostic status, with
minimal or no symptoms, and optimal functioning with
minimal impairment [88]. The likelihood of the appearance
of particular side effects differs between individuals and
between each medication class [46, 47]. Evidence-based
guidelines recognize that each patient is unique and that
treatment strategies should be tailored to an individual’s
situation, taking into account a broad range of factors
including age, type of ADHD, comorbid symptoms, treat-
ment history, and the attitudes of patients and parents/
caregivers to ADHD medications. The initial selection of
medication strategy for an individual requires consider-
ation of the class of drug, dose and desired pharmacoki-
netic properties (including speed of onset and duration of
action). Subsequent optimization of treatment involves on-
going assessment for adequate efficacy and remission of
impairment, and monitoring and treating treatment-emer-
gent adverse events and adherence to the agreed thera-
peutic regimen [1, 15, 17, 66, 75, 77, 91, 93].
Choice of stimulant class
Although group average responses to MPH and AMF in
patients with ADHD are similar, individuals may respond
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very differently to the two drugs. While approximately
two-thirds of patients typically experience improvements
in various symptom domains in response to a single stim-
ulant, if patients with an unsatisfactory response try the
alternative class of stimulant, the proportion of patients
who respond to one of the drugs may be as high as 95 %
[4, 31]. Updated response data for studies directly com-
paring MPH- and AMF-based stimulants are presented in
Table 2. Of eight studies containing data for MPH and
AMF formulations, the proportion of responders was
higher for AMF in four studies, higher for MPH in three
studies, and were equivalent in one study. In the only head-
to-head comparison of stimulants, 90 % of patients
responded to MAS, 65 % responded to MPH, and 27 %
responded to placebo [76]. When numbers of responders
for each stimulant were combined across studies, 226 of
318 patients (71 %) responded to MPH and 216 (68 %)
responded to AMF, suggesting that there is no meaningful
difference in numbers of responders for MPH and AMF in
ADHD. However, the proportion of patients responding to
either class of stimulant (287 of 316 patients 91 %) was
higher than those responding to each single stimulant.
These analyses confirm previous assertions that non-
response is uncommon when an individual is offered both a
MPH and an AMF [35], and that responses to the two
classes of stimulant, although similar in the overall ADHD
population, does vary between individuals [4]. Differences
in the metabolic pathways and mechanisms of action of
MPH and AMF (see above), the genotype of an individual
[44, 89] and the pathophysiology of their ADHD [26] may
be important factors in determining an individual’s
response to the different stimulant drugs. In terms of
clinical practice, these differential response rates support
clinical guidelines that recommend that MPH and AMF are
equally valid first-choice medications for the treatment of
ADHD, and that if the first-selected stimulant class proves
to be unsatisfactory, then a stimulant from the second class
should be tried [75, 77].
The selection of which stimulant class to start with may
be aided by methods for identifying patient subgroups that
may preferentially respond to medication, including pre-
specified and post-hoc subgroup analyses of clinical data
[11, 23, 28, 29, 54, 87]. However, there are well-accepted
constraints of both a priori and post-hoc specification [8,
56, 74, 78]. These limitations are starting to be addressed
by the development of personalized treatment selection
techniques; these combine patient characteristics from
clinical trial data to form a risk score and then performing
analyses on subgroups using a two-stage process that
allows for treatment responses at an individual level to be
made [16, 94, 102]. These methodologies have the
advantage that they can systematically use multivariate
regression models to select and combine multiple baseline
covariates from different levels of analysis to define sub-
groups. With a view to the future, pharmacogenomics and
non-genetic biomarkers may assist in the optimization and
individualization of ADHD pharmacotherapy, although
this is not yet possible [10, 19, 34, 44, 50, 89].
Choice of stimulant formulation
Reductions in the symptoms of ADHD by stimulants
depend upon achieving sufficient occupancy of their
molecular target(s) in the brain [95]. Positron emission
studies suggest that peak occupancy of the dopamine
transporter is reached approximately 60 min after oral
dosing with short-acting MPH [96]. However, the elimi-
nation half-life of short-acting MPH is reported to be
approximately 3 h [51] and of AMF to be approximately
7 h [14]. Therefore, two or, in the case of short-acting
MPH, three daily doses are necessary to maintain thera-
peutic concentrations of stimulants within the brain
throughout the day. For children and adolescents, repeat
dosing may be undesirable because of the difficulties
associated with storing and administering scheduled drugs
within a school environment, the stigma associated with
receiving medication during the school day, fragmented
coverage with multiple short-acting doses, the potential for
diversion of drug and the possible impact on adherence to
the dosing regimen [100].
To extend the duration of action (i.e. symptomatic
control) of stimulant medications, several long-acting for-
mulations of MPH and AMF have been introduced that
extend the pharmacokinetic and pharmacodynamic profile
of the drugs (Table 1) [43, 61]. Most formulations depend
on the slow, sustained release of the active ingredient in the
stomach via the use of technologies such as wax matrix
tablets, capsulated biphasic beads, or osmotically con-
trolled release systems. Long-acting formulations mean
that systemic exposure, and hence efficacy (symptom
control), is maintained for longer periods, resulting in
correspondingly improved convenience, confidentiality and
compliance, more consistent coverage, and reduced abuse
potential [43, 61, 75]. LDX is the first stimulant to use
prodrug technology to modify the delivery profile. In its
parent form, LDX is inactive and requires enzymatic
cleavage in the blood to yield AMF. The combination of
short- and long-acting formulations provides a range of
treatment options lasting from approximately 4 h to more
than 12 h. The demonstration that the efficacy of LDX in
children is maintained for at least 13 h [97], suggests that
this prodrug is the longest-acting stimulant formulation
[25, 45]. However, since the drug needs to be absorbed and
then cleaved in the bloodstream before it can be active, the
onset of action may be somewhat delayed and may occur
1.5–2 h after ingestion [97]. In selecting an ADHD
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medication, stimulants may be contraindicated or the
patient or caregivers may express a preference for non-
stimulants. In such cases, a non-stimulant such as ato-
moxetine may be considered. Generally, the non-stimulants
are considered less effective than the stimulants. Where
stimulants are considered appropriate, the choice of short-
or long-acting stimulant should be based on both clinical
requirements and the preferences of an individual and their
family [9].
Adherence to dosing regimen and persistence
on therapy
Despite the carefully managed nature of the Multimodal
Treatment Study of Children with ADHD (MTA), saliva
assays for MPH revealed that approximately 25 % of 254
patients in the medication arms of the study were non-
adherent on 50 % or more of repeated assays, and that
barely half (54 %) were adherent at every assay point [67].
Furthermore, discrepancies were uncovered between par-
ents’ reports of adherence and the outcomes of the saliva
assays [67]. These results indicate that there is considerable
potential to improve pharmacotherapy outcomes by
improving adherence. Several strands of evidence suggest
that medication adherence may be improved by tailoring
the selection of drug to an individual patient. Discrete
choice experiments suggest that long-acting stimulants,
with consistent therapeutic coverage throughout the day,
are the preferred stimulant formulations of most patients
[20, 42, 58, 64], and retrospective claims analyses suggest
that long-acting stimulants are generally associated with
enhanced adherence and persistence in patients of all ages
compared with short-acting stimulants [20, 59, 80, 83]. In
addition to drug regimens that patients find convenient,
other strategies to improve adherence include improved
communication between physicians, caregivers, and
patients; clear instruction and encouragement; peer support
groups; advice about reminders to take medication and
incorporating medication into daily routines; and the use of
positive reinforcement to improve attitudes to medication
[66]. Addressing adverse events effectively may also con-
tribute to promoting adherence.
Multimodal treatment
The importance of utilizing a multimodal treatment strat-
egy that incorporates both medication and non-drug inter-
ventions is recognized by all ADHD clinical guidelines [1,
17, 66, 75, 91]. Indeed, as mentioned previously, non-drug
interventions are the first-line treatment in school-aged
children and adolescents with moderate ADHD and mod-
erate impairment in many European countries [66, 91].
Behavioural therapy alone can produce improvements in
ADHD compared with baseline [73]. In the MTA, for
example, both medication and intensive behavioural ther-
apy provided superior treatment outcomes to treatment in
the community, even though the community treatment
often included medication [92]. As the medication arm of
the MTA was superior to both the behavioural and com-
munity treatment arms, these data provide further support
for the notion that for medication treatments to achieve
optimal effectiveness they need to be carefully titrated and
monitored. The MTA also demonstrated that there were
benefits in combining medication and behavioural therapy
in certain non-core ADHD symptom domains (including
aggression, internalizing symptoms, social skills, and par-
ent–child relations), compared with either treatment
approach alone [92]. Furthermore, non-adherence resulted
in greater deleterious effects in the medication manage-
ment group than in the combined treatment group [67]. The
results from the MTA study confirmed those of earlier
studies in children attending summer treatment pro-
grammes that demonstrated the reinforcing and synergistic
outcomes of pharmacotherapy and behavioural therapy [18,
70, 71]. Together, these data illustrate the potential thera-
peutic advantages of combining intensive behavioural
therapy with carefully crafted medication management
[81].
Conclusions
Randomized and controlled clinical trials indicate that
MPH and AMF offer robust medication options for the
treatment of ADHD. In the drive to improve the treatment
of ADHD for an individual, the nature of the stimulant, its
formulation and optimization of the dosing regimen, with
careful on-going monitoring of both positive and negative
medication effects and adherence are all important con-
siderations. Furthermore, concurrent non-drug treatments,
including behavioural therapy, should all be considered as
part of a multimodal treatment strategy. For those patients
or caregivers who prefer not to take stimulants or for whom
stimulants are contraindicated, non-stimulant drug options
are available, though generally less effective.
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